A Study of p53 immunostaining in prostate carcinomas: Correlation with Gleason’s score
DOI:
https://doi.org/10.21276/apalm.2507Keywords:
Prostate cancer, Gleason’s score, p53Abstract
Background: Prostate cancer is the second most common cause of cancer and the sixth leading cause of cancer death among men worldwide. In view of the above, early diagnosis and effective treatment of the disease are immensely important. The increasing number of options for the treatment of prostate cancer has made the prognostic evaluation of the disease even more important. P53 is a tumor suppressor gene characterised by a highly proliferative pattern and an aggressive behaviour. The Objectives was to study the immunostaining patterns of p53 in prostate cancers and to compare the results with Gleason's score.
Methods: Fifty cases of histopathologically proven prostate carcinomas diagnosed on needle biopsies and transurethral resection specimens was studied in JSS medical college and hospital, mysore for a period of 3 years and histopathological grade was assessed using Gleason grading system. Immunohistochemistry (IHC) for p53 was done on paraffin embedded wax sections.
Result: p53 staining was positive in 47(94%) cases out of 50 cases, three (6%) cases were negative. Although there was an increase in positive p53 staining with increased Gleason’s score, it was not statistically significant (‘p’ value = 0.068).
Conclusion: p53 is a tumor suppressor gene, that express high proliferative pattern. It can be used as a prognostic factor. The immunoreactivity of p53 marker with increased tumor grade can benefit patients with appropriate targeted treatment and increase their survival period.
References
2. Verma R, Gupta V, Singh J, Verma M, Gupta G et al. Significance of p53 and Ki67 expression in prostate cancer. Urology Annals 2015;7(4):488-493
3. Madani SH, Ameli S, Khazaei S, Kanani M, Izadi B. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer. Indian J Pathol Microbiol 2011;54:688-91
4. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58–64.
5. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. Part 1. 1966; 50(3): 125–8.
6. Mellinger GT, Gleason D, Bailar J. The histology and prognosis of prostatic cancer. J Urol 1967; 97(2):331–7.
7. Poulos CK, Daggy JK, Cheng L. Preoperative prediction of Gleason grade in radical prostatectomy specimens: the influence of different Gleason grades from multiple positive biopsy sites. Mod Pathol 2005; 18: 228–34.
8. Tsukamoto T, Kumamoto Y, Umehara T, Takahashi A, Shimazaki J, Ohshima H et al. Clinical study of bone-related relapse in prostate carcinoma. Adv Exp Med and Biol 1992; 324: 283–93.
9. Petrescu A, Mârzan L, Codreanu O, Niculescu L. Imunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma. Rom morphol Embryol 2006; 47(2):143-6.
10. Rubin SJ, Hallahan DE, Ashman CR, Brachman DG, Beckett MA, Virudachalam Set al. Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes. J Surg Oncol 1991;46(1):31-6.
11. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 1991;51(17):4716-20.
12. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, and Isola J. Small Subgroup of Aggressive, Highly Proliferative Prostatic Carcinomas Defined by p53 Accumulation. J Natl Cancer Inst 1992; 84(11): 883-887
13. Lin JT, Wang JS, Jiann BP, Yu CC, Tsai JY, Huang JK et al. Correlation of p53 protein accumulation and Bcl-2 overexpression with histopathological features in prostatic cancer. J Formos Med Assoc 2005;104 (11):864-7.
14. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, DeVere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 1996;27(6):573-80.
15. Shirley SE, Escoffery CT, Sargeant LA, Tulloch T. Clinicopathological features of prostate cancer in Jamaican men. BJU International 2002; 89:390-95.
16. Catalona WJ, Antenor JA, Roehl KA, Moul JW. Screening for prostate cancer in high risk populations. J Urol 2002;168:1980-84.
17. Chiusa L, Galliano D, Formiconi A, Di Primio O, Pich A. High and low risk prostate carcinoma determined by histologic grade and proliferative activity. American cancer society 1997;79:1956-63
18. Schlomm T, Iwers L, Kirstein P, Jessen B, Ko¨llermann J, Minner S, et al. Clinical significance of p53 alterations in surgically treated prostate cancers. Modern Pathology 2008;21: 1371–1378
19. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: A Cancer Journal for Clinicians 2007;57(1):43-66.
20. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53:3369-73
21. Shurbaji MS, Kalbfleisch JH, Thurmond TS. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106-9.
22. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al. p53 Status and Prognosis of Locally Advanced Prostatic Adenocarcinoma: a Study Based on RTOG 8610. J Natl Cancer Inst 1997; 89:158-65
23. Cappello F, Ribbene A, Campanella C, Czarnecka AM, Anzalone R, Bucchieri F, Palma A, Zummo G. The value of Imunohistochemical research on PCNA, p53 and heat shock proteins in prostate cancer management: a review. European Journal of Histochemistry 2006; 50(1):25-34.
24. Borre M, Stausbot-Gron B, Overgaard J. P53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. J Urol 2000;164:716-21.
25. Sasor A, Wagrowska-Danilewicz M, Danilewicz M. Ki-67Antigenand P53 protein expression in benign and malignant prostatic Lesions. Pol J Pathol 2000; 51:31-6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Roopa Urs A.N, Manjunath G V, Suchitha S, Hugara Siddalingappa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
